Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

57318 reported adverse events

Drugs of this class: LAMIVUDINE LAMIVUDINE AND ZIDOVUDINE ZIDOVUDINE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE STAVUDINE ABACAVIR AND LAMIVUDINE ABACAVIR SULFATE AND LAMIVUDINE DIDANOSINE ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE EMTRICITABINE

These side effects are most commonly reported by patients taking drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class:

# Side effect Count
0 FOETAL EXPOSURE DURING PREGNANCY 2967
1 DRUG EXPOSURE DURING PREGNANCY 2442
2 PYREXIA 2207
3 NAUSEA 2191
4 DIARRHOEA 2085
5 DRUG INTERACTION 2000
6 ANAEMIA 1912
7 VOMITING 1853
8 DRUG RESISTANCE 1626
9 FATIGUE 1504
See all common reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

Drugs of the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 IMMUNE RECONSTITUTION SYNDROME 908 0.7264
1 BLOOD HIV RNA INCREASED 305 0.7227
2 HUMAN IMMUNODEFICIENCY VIRUS TRANSMISSION 93 0.6370
3 LIPODYSTROPHY ACQUIRED 630 0.5812
4 MITOCHONDRIAL TOXICITY 218 0.5619
5 VIROLOGIC FAILURE 1015 0.5007
6 ACQUIRED GENE MUTATION 83 0.4029
7 FANCONI SYNDROME ACQUIRED 341 0.3933
8 GENOTYPE DRUG RESISTANCE TEST POSITIVE 181 0.3358
9 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 758 0.3344
See all enriched reactions for Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]